Amount of eligible clients: CDEC discussed the uncertainty in the number of clients with moderately extreme to significant hemophilia B in Canada suitable for etranacogene dezaparvovec. Clinical professionals consulted by CADTH indicated that some patients that are classified as getting mild or reasonable illness may have a significant bleeding phenotype, https://hemgenix04930.activosblog.com/34914868/5-easy-facts-about-hemgenix-described